MUC-1 CD40L dendritic cell vaccine - MicroVAX

Drug Profile

MUC-1 CD40L dendritic cell vaccine - MicroVAX

Alternative Names: Ad-sig-hMUC-1/ecdCD40L; CD40L MUC-1 dendritic cell vaccine; Mucin antigen vaccine - MicroVAX

Latest Information Update: 19 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MicroVAX
  • Developer MicroVAX; National Cancer Centre (Singapore)
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 May 2016 Phase-I development is ongoing in Singapore
  • 12 Aug 2014 Phase-I clinical trials in Solid tumours in Singapore (Parenteral)
  • 13 Mar 2013 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top